BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have earned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $401.00.

A number of brokerages have weighed in on ONC. Morgan Stanley reaffirmed an “overweight” rating and issued a $405.00 target price on shares of BeOne Medicines in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Barclays raised their price target on shares of BeOne Medicines from $394.00 to $405.00 and gave the company an “overweight” rating in a report on Friday, February 27th. Guggenheim boosted their price objective on shares of BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Wall Street Zen downgraded BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th.

Insiders Place Their Bets

In other news, SVP Chan Henry Lee sold 341 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John Oyler sold 24,369 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total value of $7,380,639.03. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 102,665 shares of company stock valued at $31,561,896. 6.62% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Several large investors have recently bought and sold shares of ONC. ProShare Advisors LLC acquired a new position in BeOne Medicines in the second quarter valued at approximately $373,000. KBC Group NV acquired a new stake in BeOne Medicines during the 2nd quarter worth $2,175,000. PNC Financial Services Group Inc. bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at $228,000. Geode Capital Management LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at $8,622,000. Finally, Fiera Capital Corp acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at $5,062,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Stock Performance

Shares of NASDAQ:ONC opened at $284.05 on Friday. The business has a fifty day moving average of $334.52 and a 200-day moving average of $329.69. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. BeOne Medicines has a twelve month low of $196.45 and a twelve month high of $385.22. The firm has a market cap of $31.15 billion, a PE ratio of 112.72 and a beta of 0.53.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%.The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. On average, equities research analysts predict that BeOne Medicines will post -5.82 EPS for the current fiscal year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.